2Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement [C]. CLSI/NCCLS document M100-S15. 2005, 25:114-141.
3Fiebelkonn KR, Crawford SA, McElmeel ML. et al. Practical disk diffusion method for Inducible clindamycin resistance in staphylococcus aureus and coagulase-negative staphylococci [J]. J Clin Microbiol, 2003, 4740-4744.
7Fridkin S K. Vancomycin- intermediate and - resistant Staphylococcus aureus: what the infectious disease specialist needs to know [J]. Clin Infect Dis ,2001,32(1) :108.
8Boyle - Vavra S, Berke S K, Lee J C, et al. Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus tutreus Clinical Isolates [ J ] . Antimicrob Agents Chemother , 2000,44(2 ) : 272.
9Chadwick P R, Wooster S L. Glycopeptide Resistance in Staphylococcus aureus [J]. J Infec ,2000,40:211.
10Tenover F C, Biddle J W, Lancaster M V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus [ J]. Emerg Infect Dis, 2001,7 : 327.
